AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20587582 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid controls
Number of subjects: 25
Study 19431244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortexin, 20 mg daily for 10 days
Number of subjects: 62
Study 19431244 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 20 mg daily for 10 days
Number of subjects: 62
Study 16594814 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 forms of a 6-month pharmaco-psychotherapy program
Number of subjects: 599
Study 14644895 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (HT)
Number of subjects: 0
Study 10878069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle sequencing
Number of subjects: 0
Study 10878069 — intervention group
Group type: COMPARATOR
Intervention: Hybridization sequencing
Number of subjects: 0
Study 10878069 — intervention group
Group type: COMPARATOR
Intervention: Population-based hybridization sequencing
Number of subjects: 0
Study 10878069 — intervention group
Group type: EXPERIMENTAL
Intervention: Population cycle sequencing
Number of subjects: 0
Study 9185371 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention in schools
Number of subjects: 1689
Study 9185371 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1689
Study 8365196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of extending the duration of the trial
Number of subjects: 0
Study 8365196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of increasing the number of participants
Number of subjects: 0
Study 8365196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of delay in accrual
Number of subjects: 0
Study 8365196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost effectiveness of retention activities
Number of subjects: 0
Study 2868294 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunisation of the donor alone
Number of subjects: 38
Study 2868294 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunisation of both donor and recipient
Number of subjects: 38
Study 31674202 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing cranberry, D-mannose and anti-inflammatory molecules, taken twice a day for 2 weeks starting from surgery
Number of subjects: 40
Study 31674202 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (Control)
Number of subjects: 40
Study 29185674 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT+KT
Number of subjects: 42
Study 29185674 — intervention group
Group type: COMPARATOR
Intervention: ESWT
Number of subjects: 42
Study 27887579 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin (750 mg intravenous once daily for 7 days)
Number of subjects: 370
Study 27887579 — intervention group
Group type: COMPARATOR
Intervention: ceftolozane/tazobactam (1.5 g intravenous every 8 h for 7 days)
Number of subjects: 370
Study 24636796 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtelephonic ECG system (TTECG)
Number of subjects: 775
Study 24636796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TTECG)
Number of subjects: 775
Study 22417251 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-based screening
Number of subjects: 182160
Study 22417251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 182160
Study 20694783 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines administered according to syndrome typing for oral intake and external washing
Number of subjects: 76
Study 20694783 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine hydrochloride and Celecoxib, combined with intra-articular injection of sodium hyaluronate and peri-articular pain spot blocking with Triamcinolone Acetonaide Acetate injection
Number of subjects: 76
Study 18279899 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) added to the soup during training sessions.
Number of subjects: 32
Study 18279899 — intervention group
Group type: COMPARATOR
Intervention: Control condition (soup unchanged, no MSG added).
Number of subjects: 32
Study 18279899 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) paired with the soup during training.
Number of subjects: 32
Study 16150070 — intervention group
Group type: EXPERIMENTAL
Intervention: Early case conferencing within 24 hours of admission
Number of subjects: 25
Study 16150070 — intervention group
Group type: COMPARATOR
Intervention: Standard evaluation procedures (control)
Number of subjects: 25
Study 12859160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg daily)
Number of subjects: 60
Study 12859160 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 10580945 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD)
Number of subjects: 146
Study 10580945 — intervention group
Group type: COMPARATOR
Intervention: No CAD
Number of subjects: 146
Study 8945035 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping biphasic (OLBI) pacing at mid-RA
Number of subjects: 12
Study 8945035 — intervention group
Group type: COMPARATOR
Intervention: Unipolar stimulation
Number of subjects: 12
Study 8945035 — intervention group
Group type: COMPARATOR
Intervention: Bipolar stimulation
Number of subjects: 12
Study 8945035 — intervention group
Group type: EXPERIMENTAL
Intervention: OLBI pacing
Number of subjects: 12
Study 8945035 — intervention group
Group type: COMPARATOR
Intervention: Diaphragmatic pacing
Number of subjects: 12
Study 8945035 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing threshold on day 0 vs day 2
Number of subjects: 12
Study 1681917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g plus metronidazole 1.5 g once daily (n = 94)
Number of subjects: 190
Study 1681917 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 2 g plus netilmicin 150 mg twice daily plus metronidazole 1.5 g once daily (n = 96)
Number of subjects: 190
Study 1681917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus metronidazole
Number of subjects: 190
Study 1681917 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus netilmicin plus metronidazole
Number of subjects: 190
Study 7023519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.02 mg kg‐1
Number of subjects: 60
Study 7023519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg kg‐1
Number of subjects: 60
Study 31331027 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Protein (LP) formula
Number of subjects: 0
Study 31331027 — intervention group
Group type: COMPARATOR
Intervention: Higher-Protein (HP) formula
Number of subjects: 0
Study 27956248 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized cryoballoon (CB) pulmonary vein isolation (PVI) with no bonus freeze if TTI <75 seconds
Number of subjects: 100
Study 27956248 — intervention group
Group type: COMPARATOR
Intervention: Control group with acute PVI followed by 1 empiric bonus freeze
Number of subjects: 100
Study 27956248 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized cryoballoon (CB) pulmonary vein isolation (PVI)
Number of subjects: 100
Study 26898832 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 48
Study 26898832 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 48
Study 24637941 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg t.i.d. sorafenib
Number of subjects: 41
Study 24637941 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg b.i.d. sorafenib
Number of subjects: 41
Study 21698556 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (psycho-educational program)
Number of subjects: 233
Study 21698556 — intervention group
Group type: COMPARATOR
Intervention: Instruction (short instruction)
Number of subjects: 233
Study 18094220 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 400/100 mg bid
Number of subjects: 18
Study 18094220 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin 500 mg bid
Number of subjects: 18
Study 18094220 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 400/100 mg bid plus clarithromycin 500 mg bid
Number of subjects: 18
Study 16801665 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoablation and autologous hematopoietic stem cell transplantation
Number of subjects: 9
Study 16801665 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogous therapy in a patient with non‐CNS lymphoma
Number of subjects: 9
Study 12972124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacemaker implantation
Number of subjects: 0
Study 12972124 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacemaker implantation
Number of subjects: 0
Study 10751473 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging delay of 15 seconds
Number of subjects: 75
Study 10751473 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging delay of 25 seconds or later
Number of subjects: 75
Study 8624887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine 5 mg, repeated after 15 minutes if DBP > 120 mmHg
Number of subjects: 200
Study 8624887 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydrallazine 5 mg, repeated after 15 minutes if DBP > 120 mmHg
Number of subjects: 200
Study 1419549 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg cephradine 12-hourly for seven days
Number of subjects: 113
Study 1419549 — intervention group
Group type: COMPARATOR
Intervention: 125 mg cefuroxime axetil 12-hourly for seven days
Number of subjects: 113
Study 3973648 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) alone, 600 mg/m2 IV once weekly
Number of subjects: 148
Study 3973648 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) plus radiation therapy, 4,000 rad, with adjuvant 5-FU, 600 mg/m2 IV for the first three days of radiotherapy, then maintenance 5-FU, 600 mg/m2 weekly
Number of subjects: 148
Study 3973648 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 148
Study 3973648 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) plus radiation therapy
Number of subjects: 148
Study 31740072 — intervention group
Group type: COMPARATOR
Intervention: Open Radical Cystectomy (ORC)
Number of subjects: 60
Study 31740072 — intervention group
Group type: COMPARATOR
Intervention: Robotic-Assisted Radical Cystectomy (RARC)
Number of subjects: 60
Study 31740072 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Radical Cystectomy (LRC)
Number of subjects: 60
Study 29458423 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiring Futures parenting programme (group-based for 10-12 weeks and one-to-one for up to 12 weeks)
Number of subjects: 248
Study 29458423 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 248
Study 28647736 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg of vitamin D3 supplementation daily
Number of subjects: 987
Study 28647736 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 µg of vitamin D3 supplementation daily
Number of subjects: 987
Study 28647736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 10 µg and 30 µg of vitamin D3 supplementation
Number of subjects: 987
Study 26427968 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate applied topically together with propranolol given orally
Number of subjects: 39
Study 26427968 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol given orally
Number of subjects: 39
Study 26427968 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate applied topically
Number of subjects: 39
Study 23246368 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 36
Study 23246368 — intervention group
Group type: COMPARATOR
Intervention: MenPS (control)
Number of subjects: 36
Study 22013143 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2α (3.5 µg/kg/min over 20 min)
Number of subjects: 12
Study 22013143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22013143 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2α
Number of subjects: 12
Study 19485589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) with minimal parent involvement
Number of subjects: 119
Study 19485589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) with active parent involvement
Number of subjects: 119
Study 16996597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime systolic ABP
Number of subjects: 194
Study 16996597 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean ABP
Number of subjects: 194
Study 16996597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime to daytime APR ratio
Number of subjects: 194
Study 16996597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondipper status
Number of subjects: 194
Study 12957721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1315
Study 12957721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 1315
Study 12957721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1315
Study 11204513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 12
Study 11204513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9104900 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients (angina reported)
Number of subjects: 558
Study 9104900 — intervention group
Group type: EXPERIMENTAL
Intervention: History of angina within 6 weeks before randomization
Number of subjects: 558
Study 9104900 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina during ambulatory electrocardiogram or stress test
Number of subjects: 558
Study 9104900 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic patients (no angina reported)
Number of subjects: 558
Study 1552888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam (CTM-L group)
Number of subjects: 332
Study 1552888 — intervention group
Group type: COMPARATOR
Intervention: Cefotiam (CTM-H group)
Number of subjects: 332
Study 1552888 — intervention group
Group type: COMPARATOR
Intervention: Cefmenoxime (CMX-H group)
Number of subjects: 332
Study 3553480 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/day elemental calcium for 4 weeks
Number of subjects: 32
Study 3553480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30149850 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Number of subjects: 158
Study 30149850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Number of subjects: 158
Study 30149850 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injection
Number of subjects: 158
Study 30149850 — intervention group
Group type: EXPERIMENTAL
Intervention: Local corticosteroid injection
Number of subjects: 158
Study 27093511 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath laryngoscope
Number of subjects: 41
Study 27093511 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 41
Study 27093511 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC laryngoscope
Number of subjects: 41
Study 27093511 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 41
Study 27093511 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study 24899709 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (200 mg/d)
Number of subjects: 46
Study 24899709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 22939758 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose grass pollen SLIT
Number of subjects: 207
Study 22939758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 20303198 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 410
Study 20303198 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 410
Study 18337059 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (GT) 2 g of leaves in 200 mL of water, three times per day for 7 days
Number of subjects: 14
Study 18337059 — intervention group
Group type: COMPARATOR
Intervention: Control group (no green tea)
Number of subjects: 14
Study 16801459 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (n=37)
Number of subjects: 54
Study 16801459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=17)
Number of subjects: 54
Study 14643036 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary bladder catheterization
Number of subjects: 270
Study 14643036 — intervention group
Group type: COMPARATOR
Intervention: No catheterization (Control)
Number of subjects: 270
Study 10926708 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-containing lotion
Number of subjects: 54
Study 10926708 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream
Number of subjects: 54
Study 10926708 — intervention group
Group type: COMPARATOR
Intervention: Control lotion
Number of subjects: 54
Study 8828530 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (MK-0476), 200 mg, three times daily for 10 1/3 days
Number of subjects: 29
Study 8828530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1467051 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis of left ventricular regional wall motion
Number of subjects: 66
Study 1467051 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous echocardiographic examination
Number of subjects: 66
Study 6377525 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 100 micrograms in 8 ml normal saline
Number of subjects: 31
Study 6377525 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1.5 mg/kg 4-6-hourly as required
Number of subjects: 31
Study 30175844 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 119
Study 30175844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 29024718 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpleural catheter
Number of subjects: 86
Study 29024718 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative incision site injection
Number of subjects: 86
Study 27291639 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-h nightly sleep opportunity (Sleep Restriction)
Number of subjects: 56
Study 27291639 — intervention group
Group type: COMPARATOR
Intervention: 9-h nightly sleep opportunity (Control)
Number of subjects: 56
Study 24646201 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit
Number of subjects: 0
Study 24646201 — intervention group
Group type: COMPARATOR
Intervention: Pap test reminder letter
Number of subjects: 0
Study 22456780 — intervention group
Group type: EXPERIMENTAL
Intervention: MEB complexed with chitin nano-crystals (topical emulsion and oral hard capsules)
Number of subjects: 70
Study 22456780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20068255 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physiotherapy including manual lymph drainage, massage of scar tissue, and progressive active and action assisted shoulder exercises, along with an educational strategy
Number of subjects: 120
Study 20068255 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only the educational strategy
Number of subjects: 120
Study 17885011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cava (30 g ethanol/d for 28 days)
Number of subjects: 20
Study 17885011 — intervention group
Group type: COMPARATOR
Intervention: Gin (30 g ethanol/d for 28 days)
Number of subjects: 20
Study 15831802 — intervention group
Group type: EXPERIMENTAL
Intervention: Glu+Caf (48 g/h + 5 mg x kg(‐1) x h(‐1))
Number of subjects: 8
Study 15831802 — intervention group
Group type: EXPERIMENTAL
Intervention: Glu (48 g/h)
Number of subjects: 8
Study 15831802 — intervention group
Group type: COMPARATOR
Intervention: Wat (plain water)
Number of subjects: 8
Study 11814529 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 318
Study 11814529 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 318
Study 11814529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 10414411 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (6 or 24 microg)
Number of subjects: 12
Study 10414411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8776078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 55% VO2max
Number of subjects: 20
Study 8776078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 70% VO2max
Number of subjects: 20
Study 8776078 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 20
Study 2341993 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital counselling in addition to routine care
Number of subjects: 60
Study 2341993 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 60
Study 7322717 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (daily for a mean of 35 months)
Number of subjects: 50
Study 7322717 — intervention group
Group type: COMPARATOR
Intervention: No phenobarbital
Number of subjects: 50
Study 31455305 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (PA)
Number of subjects: 841
Study 31455305 — intervention group
Group type: EXPERIMENTAL
Intervention: Compositional data analysis
Number of subjects: 841
Study 31455305 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate pattern analysis
Number of subjects: 841
Study 31455305 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression
Number of subjects: 841
Study 28231822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (50 mg) twice per day as an add-on therapy combined with AChEIs
Number of subjects: 60
Study 28231822 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving cilostazol)
Number of subjects: 60
Study 27128214 — intervention group
Group type: EXPERIMENTAL
Intervention: FSK0808
Number of subjects: 0
Study 27128214 — intervention group
Group type: COMPARATOR
Intervention: Reference filgrastim (Gran(®))
Number of subjects: 0